ETOPOPHOS (etoposide phosphate) for Injection is an antineoplastic agent which is available for intravenous infusion as a sterile lyophile in single-dose vials containing etoposide phosphate equivalent to 100 mg etoposide, 32.7 mg sodium citrate USP, and 300 mg dextran 40. Etoposide phosphate is a water soluble ester of etoposide (commonly known as VP-16), a semi-synthetic derivative of podophyllotoxin. The water solubility of etoposide phosphate lessens the potential for precipitation following dilution and during intravenous administration.
ETOPOPHOS for Injection is indicated in the management of the following neoplasms:
Refractory Testicular Tumors- ETOPOPHOS for Injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy.
Small Cell Lung Cancer- ETOPOPHOS for Injection in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.
Published Studies Related to Etopophos (Etoposide)
Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. [2011.08.27]
In 1991, a prospective phase II trial was initiated to evaluate the efficacy of treatment for adults with medulloblastoma (MB). After surgery, patients were staged with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology.To know whether adding chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). [2011.05]
CONCLUSION: This study could not demonstrate that high-dose chemotherapy given as part of first-line therapy improves outcome in patients with poor-prognosis GCC.
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. [2011.03]
PURPOSE: A randomized clinical trial examined whether dexamethasone administration prior to ondansetron followed by etoposide and carboplatin infusions, and single-nucleotide polymorphisms (SNPs) of CYP3A4, CYP3A5 and MDR1 genes could modify etoposide pharmacokinetics in pediatric patients... CONCLUSION: Pharmacokinetics of etoposide was influenced by BW on an allometric basis in this pediatric population. Dexamethasone did not influence etoposide pharmacokinetics during these 3-5 days courses. These results should allow a better individualization of etoposide dosing in children.
Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. [2011.01]
Darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), is used in cancer patients as a supportive care for anemia. For small-cell lung cancer (SCLC), several studies have shown that the administration of ESAs does not affect survival but decreases the need for blood transfusions and improves the quality of life (QOL) of patients receiving chemotherapy...
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. [2010.12.01]
CONCLUSIONS: The overall rate of Grade 2 to 5 RP was 7% in patients treated with chemoradiotherapy. In this analysis, predictive factors for RP were MLD > 18 Gy and treatment with CD. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Clinical Trials Related to Etopophos (Etoposide)
Ph II Bev + Either Temo/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan [Active, not recruiting]
Primary objective To estimate 6-month progression free survival probability of pts w
recurrent GBM treated w bev + either daily temo/etoposide following progression on bev +
irinotecan Secondary Objectives To evaluate safety & tolerability of bev + either daily
temo/etoposide among pts w recurrent GBM who have progressed on bev + irinotecan To evaluate
radiographic response, progression free survival & overall survival of pts w recurrent GBM
treated w bev + either daily temo/etoposide following progression on bev + irinotecan
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas [Recruiting]
Primary Objective To determine maximum tolerated dose & dose limiting toxicity of vandetanib
when combo w standard dosing of etoposide among pts w recurrent malignant glioma who are on
& not on enzyme-inducing anti-epileptic drugs Secondary Objectives To assess safety &
tolerability of vandetanib + etoposide in population To evaluate pharmacokinetics of
vandetanib among malignant glioma pts on & not on EIAEDs when combo w etoposide Exploratory
Objective To evaluate for evidence of anti-tumor activity of study regimen among recurrent
malignant glioma pts including radiographic response rate, 6-month progression free survival
rate & median PFS
Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer [Recruiting]
The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival
in comparison to a regimen containing etoposide and without platinum derivative.
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer [Recruiting]
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923
administered in combination with carboplatin and etoposide followed by BMS-833923 alone in
subjects with extensive-stage Small Cell Lung Cancer (SCLC).
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer [Recruiting]
The Phase I portion of the study is to assess the maximum tolerated dose of vorinostat when
combined with carboplatin plus etoposide. The Phase II portion is to determine
progression-free survival among patients with extensive disease small cell lung cancer
receiving carboplatin plus etoposide with vorinostat.